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MICROMECHANICAL DEVICES FOR
CONTROL OF CELL-CELL INTERACTION,
AND METHODS OF USE THEREOF
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a national stage application, filed under
35 U.S.C. §371, of International Application No. PCT/
US2008/056403, filed on Mar. 10, 2008, which claims the
benefit of and priority to U.S. Patent Application Ser. No.
60/900,558, filed Feb. 8, 2007, the disclosure of each is
incorporated by reference herein.
Each of the applications and patents cited in this text, as
well as each document or reference cited in each of the
applications and patents (including during the prosecution of
each issued patent; "application cited docutments"), and
each of the U.S. and foreign applications or patents corre-
sponding to and/or claiming priority from any of these
applications and patents, and each of the documents cited or
referenced in each of the application cited documents, are
hereby expressly incorporated herein by reference. More
generally, documents or references are cited in this text,
either in a Reference List before the claims, or in the text
itself; and, each of these documents or references ("herein-
cited references"), as well as each document or reference
cited in each of the herein-cited references (including any
manufacturer's specifications, instructions, etc.), is hereby
expressly incorporated herein by reference. Documents
incorporated by reference into this text may be employed in
practice of the invention.
RELATED APPLICATIONS
This application claims the benefit of priority to U.S.
Provisional Patent Application Ser. No. 60/893,736, filed
Mar. 8, 2007; which is hereby incorporated by reference in
its entirety.
GOVERNMENT SUPPORT
This invention was made with support from the National
Institutes of Health, NCI/NASA UIP, NIH NIDDK, NSF and
DARPA-MTO; therefore, the government has certain rights
in the invention.
BACKGROUND OF THE INVENTION
Mammalian cells in vivo integrate and respond to cues in
their microenvironment that vary in both time and space. In
particular, interactions between neighboring cells can regu-
late both the fate and function of individual cells as well as
govern the emergent properties of the resultant tissue.
Because such cell-cell interactions occur primarily through
direct contact or exchange of soluble factors, understanding
the temporal and spatial aspects of these signals is of
fundamental importance to tissue biology. Recent advances
in cell ` micropatterning' have already proven invaluable in
increasing our understanding of the structure-function rela-
tionships of such multicellular communities (El-Ali, J.,
Sorger, P. K. & Jensen, K. F. (2006) Nature 442, 403-11;
Bhatia, S. N., Balis, U. J., Yarmush, M. L. & Toner, M.
(1999) Faseb J 13, 1883-900; Nelson, C. M., Jean, R. P.,
Tan, J. L., Liu, W. F., Sniadecki, N. J., Spector, A. A. &
Chen, C. S. (2005) Proc Natl Acad Sci USA 102, 11594-9;
and Liu, W. F., Nelson, C. M., Pirone, D. M. & Chen, C. S.
2
(2006) J. Cell Biol. 173, 431-441). However, dynamic
manipulation of tissue structure in vitro has remained largely
out of reach.
Previous efforts towards spatio-temporal control of tissue
5 organization at the cellular scale have focused on modula-
tion of the adhesive properties of the culture substrate
(Okano, T., Yamada, N., Okuhara, M., Sakai, H. & Sakurai,
Y. (1995) Biomaterials 16, 297-303; Lahann, J., Mitragotri,
S., Tran, T. N., Kaido, H., Sundaram, J., Choi, I. S., Hoffer,
to S., Somorjai, G. A. & Langer, R. (2003) Science 299, 371-4;
and Jiang, X., Ferrigno, R., Mrksich, M. & Whitesides, G.
M. (2003) J Am Chem Soc 125, 2366-7.). Through the
micropatterning of surface chemistries that can be dynami-
15 cally altered, localized attachment and release of cells has
been demonstrated (Cheng, X. H., Wang, Y. B., Hanein, Y.,
Bohringer, K. F. & Ratner, B. D. (2004) Journal of Bio-
medical Materials Research Part A 70A, 159-168; and Yeo,
W. S., Yousaf, M. N. & Mrksich, M. (2003) JAm Chem Soc
20 125, 14994-5). Nonetheless, these manipulations are typi-
cally not reversible (i.e., nonadhesive surfaces are rendered
adhesive just once), they do not allow the decoupling of
processes associated with adhesion from those correlated
with cell-cell interaction (i.e., attachment, spreading, and
25 contact with neighboring cells have overlapping time
scales), nor can these platforms accommodate serial
manipulations to mimic key biological events (i.e., sequen-
tial exposure of a target cell population to different inducer
populations). Manipulations of surface chemistry are also
30 limited by the inability to precisely control tissue composi-
tion: sequential seeding of different cell types can result in
contamination of pure populations and maintaining micron-
scale proximity of two cell populations in the absence of
contact over many days important for decoupling the
35 relative role of contact and paracrine signals has not been
achieved.
SUMMARY OF THE INVENTION
40 The development and function of living tissues depends
largely on interactions between cells that can vary in both
time and space; however, temporal control of cell-cell
interaction is experimentally challenging. By employing a
micromachined substrate with moving parts, herein is dis-
45 closed the dynamic regulation of cell-cell interactions via
direct manipulation of adherent cells with micron-scale
precision. The inventive devices and methods allow
mechanical control of both tissue composition and spatial
organization. The inventive device and methods enable the
50 investigation of dynamic cell-cell interaction in a multitude
of applications, such as intercellular communication, span-
ning embryogenesis, homeostasis, and pathogenic pro-
cesses.
In one specific embodiment, the utility of the inventive
55 devices and methods in deconstructing the dynamics of
intercellular communication between hepatocytes and sup-
portive stromal cells in co-culture is demonstrated. Specifi-
cally, the findings disclosed herein indicate that the main-
tenance of the hepatocellular phenotype by stroma requires
6o direct contact for a limited time (on the order of hours)
followed by a sustained soluble signal which has an effective
range of less than about 400 µm.
In another embodiment, use of the inventive devices and
methods to characterize the microenvironmental regulation
65 of sinusoidal endothelial cell phenotypes is demonstrated.
Specifically, disclosed are novel microenvironmental regu-
lators of the liver sinusoidal endothelial cells (LSEC) phe-
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notype, which may be important for the development of
better in vitro models of liver disease.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 depicts micromechanical substrates which enable
micrometer-resolution cell positioning. (A) Microfabricated
silicon parts can be fully separated (left), or locked together
with comb fingers in contact (middle) or slightly separated
(right). Cells are cultured on the top surfaces; manual
scraping can be used to restrict cells to the comb fingers only
(inset). The slope of the tapered comb fingers results in a
20:1 mechanical transmission ratio; that is, sliding the parts
1.6 mm changes the gap between the fingers by only 80 µm.
Together with the integrated snap-lock mechanism, it is
thereby possible to control separation with repeatable
micrometer-scale precision using unassisted manual actua-
tion. (B and C) Brightfield images of hepatocytes (darker
cells) and 3T3 fibroblasts cultured on the comb fingers. The
silicon is first functionalized by spin-coating with polysty-
rene followed by plasma treatment, resulting in a surface
comparable to tissue culture plastic. Devices can be reused
multiple times (>20). (D) Devices in a standard 12-well
plate. Cell culture and functional assays are performed using
standard methods. Actuation is also performed directly on
the plate using sterile tweezers. (E) One embodiment of
micromechanical substrates which enable micrometer-reso-
lution cell positioning.
FIG. 2 depicts the results of reconfigurable cell culture
studies. Cultures can be reversibly switched to initiate or to
eliminate contact between two cell populations; individual
populations can also be removed and replaced. (A) Fluo-
rescent images illustrating possible device manipulations.
Each cell type was pre-labeled with an individual dye color.
(B) Fluorescent image showing intimate contact between
hepatocytes (green) and stroma (red, 3T3 fibroblasts) at the
interface between neighboring comb fingers. Image was
taken 18 h following initiation of contact. Cell nuclei
counterstained in blue. (C) Cross-migration of cells is mini-
mal for moderate durations of contact. Representative fluo-
rescent image showing small numbers of stromal cells (red,
arrows indicate selected cells) remaining behind on a
hepatocyte finger (green) after combs were separated fol-
lowing 18 h of contact. In this work, contact was limited to
18 h in order to minimize cross-migration, but longer
durations are possible with other cell types (data not shown).
FIG. 3 depicts results of dynamic regulation of hepato-
cyte-stromal interactions, which reveals temporal dependen-
cies in intercellular communication. (A) Contact between
hepatocyte and fibroblast combs was required to maintain
albumin secretion over a 2-wk period (red). In the gap mode
(blue), function dropped almost as rapidly as with hepato-
cytes alone (green). (B) An 18-h period of transient initial
contact followed by long-term culture in the gap mode
(which allows diffusion of paracrine signals) resulted in
sustained liver-specific function (blue) similar to that
obtained with sustained contact (red). However, 18 h of
initial contact followed by removal of adjacent stroma
resulted in deterioration of function (green). (C) Following
18 h of initial contact, stroma were removed and replaced by
nave stroma (in gap mode). Liver-specific function was
maintained at similar levels (blue) to that obtained with no
cell swapping (red). In a parallel experiment in which nave
hepatocytes were substituted, liver-specific function was not
maintained (green).
FIG. 4 depicts results which show the use of spatial
reconfiguration to reveal short-range soluble signaling. (A)
_►,
Following 18 h of initial contact, hepatocytes and stroma
were separated into individual wells. Stromal conditioned
media was transferred every 2 days to the hepatocytes, but
liver-specific function declined (blue). In contrast, transient
5 contact followed by microscale separation (using the gap
mode) resulted in sustained function (red). (B) Loss in
liverspecific function progresses to loss in hepatocyte viabil-
ity. Hepatocyte viability was probed using a membrane
integrity dye (calcein AM, green) with a nuclear counterstain
io for both cell types (blue). Following initial contact, cultures
were maintained for two weeks in the gap mode, resulting in
a sharp gradient in hepatocyte viability dependent on prox-
imity to stroma (n>3, representative image shown). Selected
comb fingers are outlined in white for clarity. (C) Quantified
15 calcein fluorescence along the length of a comb finger (n=9).
L, the characteristic decay length of viability, is measured to
be 325 µm using an exponential fit over x>0.
FIG. 5 depicts one proposed model for intercellular com-
munication. Maintenance of liver-specific function in
20 hepatocytes requires (1) an initial short-term (T is about 18
h) contact-mediated signal from stromal cells, followed by
(2) sustained short-range (L is about 325 µm) soluble
signaling from the stroma.
FIG. 6 depicts results demonstrating that micromechani-
25 cal substrates can be generalized to other cell types and
biological techniques. (A) Bipotential mouse embryonic
liver progenitor cells cultured for 1 day on a micromechani-
cal substrate. The BMEL cell line, 9A1, was provided by Dr.
Mary Weiss (Institut Pasteur) and cultured as described
30 previously (Strick-Marchand, H., Morosan, S., Charneau, P.,
Kremsdorf, D. & Weiss, M. C. (2004) Proc Natl Acad Sci
USA 101, 8360-5; and Strick-Marchand, H. & Weiss, M. C.
(2002) Hepatology 36, 794-804). In brief, cells were cul-
tured on collagen in RPMI 1640 medium with glutamax
35 (Invitrogen, Carlsbad, Calif.), containing 30 ng/mL human
IGF-II (Peprotech, Rocky Hill, N.7.), 50 ng/mL human EGF
(Peprotech), and 10 mg/mL recombinant human insulin
(Invitrogen). (B) Primary rat liver sinusoidal endothelial
cells (LSEC) cultured for 1 day on a collagen-coated micro-
40 mechanical substrate. Briefly, LSEC were isolated from the
nonparenchymal fraction of the liver through a 25%/50%
Percoll gradient (Zhang, B., Borderie, D., Sogni, P., Sou-
brane, O., Houssin, D. & Calmus, Y. (1997) J Hepatol 26,
1348-55) and cultured in the presence of VEGF (R&D
45 Systems, Minneapolis, Minn.). (C) OP9 bone marrow
stromal cells (ATCC, Manassas, Va.) cultured for 1 day on
a collagen-coated micromechanical substrate, using alpha
minimum essential medium without ribonucleosides and
deoxyribonucleosides with 2 mM L-glutamine and 1.5 g/L
50 sodium bicarbonate, 80%; fetal bovine serum, 20% (all from
Invitrogen). (D) Cells can be transfected with siRNA while
adhered to micromechanical substrates, allowing selective
delivery using the separated mode. Fluorescent image of
Swiss 3T3 fibroblasts transfected with siRNA sequence
55 (against Lamin A) with FITC fluorophore conjugated to 5'
end of sense strand (Dharmacon, Lafayette, Colo.). Trans-
fection was performed using Lipofectamine 2000 (Invitro-
gen) on cells adhered to the substrate.
FIG. 7 depicts intermediates in one approach to device
60 fabrication.
FIGS. 8a and 8b depict a table of Selected Immune
Cytokines and Their Activities. Key: CTL: cytotoxic T
lymphocytes; DC: dendritic cells; GM-CSF: Granulocyte-
Monocyte Colony Stimulating Factor; IL: interleukin; IFN:
65 Interferon; TGF: Tumor Growth Factor; TNF: Tumor Necro-
sis Factor. Note that "*" indicates that italicized activities are
inhibited.
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FIG. 9 depicts data showing that LSEC lose their differ-
entiated phenotype when cultured ex vivo. (A) Specifically,
there is a strong decrease in the LSEC-specific marker SE-I
and an increase in the non-specific endothelial marker
PECAM-1, comparing cells at I day versus 3 days of
culture. There is no significant change in RECA observed.
(B) In vivo, SE-I is shown to mark the cells in the sinusoidal
vascular endothelium, the site of the LSEC. PECAM-1 is
shown to mark cells in larger diameter blood vessels, the site
of vascular endothelial cells.
FIG. 10 depicts data showing that LSEC, when in co-
culture with supportive cell types, can maintain their differ-
entiated phenotype (expression of SE-1) for up to 14 days.
The optimum maintenance is obtained in the case where
LSEC are cultured with both hepatocytes and 31`3 fibro-
blasts together. This is demonstrated by immunofluores-
cence (top) as well as by Western Blot (bottom). Direct
cell-cell contact did not appear to be necessary for mainte-
nance of SE-I expression (bottom). (Top) Use of the micro-
mechanical substrates enables organization of the cell types
to facilitate identification during microscopy. (Bottom) Use
of the micromechanical substrates enables LSEC to be
separated from the support cells prior to Western Blot
analysis, resulting in a clean measurement from a purified
cell population.
FIG. 11 depicts data showing LSEC proliferation as a
function of various supportive cell types in co-culture.
Maximum proliferation is obtained in co-culture with
hepatocytes (either alone or together with 31`3 fibroblasts).
Proliferation is measured via incorporation of BrdU.
FIG. 12 depicts examples of molds for casting polymer
replicas of the microfabricated silicon parts. (A) PDMS
mold cast from one embodiment of a comb component of the
invention. (B) Silicon wafer parts from which device ele-
ments have been cut are reassembled on a PDMS base to
form a cavity in which replica parts may be cast.
FIG. 13 depicts population-specific readout or selective
interrogation. Hepatocytes and 31`3 fibroblasts are co-cul-
tured to maintain hepatocyte differentiation. In (A) the drug
Pyrilamine is introduced while the cells are in co-culture. By
using the micromechanical substrates, the two cell popula-
tions are separated prior to viability assay, allowing the
viability of each cell type to be assessed independently. The
31`3 are shown to be more sensitive to the toxic effects of
Pyrilamine. In (B) the effect of the drug Methapyrilamine is
compared when the cells are in co-culture or when the 31`3
are alone. The 31`3 are shown to be more sensitive to the
toxic effects of the drug when alone.
FIG. 14 depicts the dynamic responses of intracellular
signaling kinases within hepatocytes during the first 120
minutes in response to the introduction of 31`3 cells in
co-culture. By using the micromechanical substrates,
hepatocytes are brought into contact with 31`3 fibroblasts for
a short, defined period of time and then separated back to a
pure hepatocyte population prior to cell lysis. The phospho-
rylation of various kinases was then measured using a
cytometeric bead array.
DETAILED DESCRIPTION OF THE
INVENTION
Overview. Cellular behavior within tissues is driven by
environmental cues that vary temporally and spatially with
a granularity on the order of individual cells. Local cell-cell
interactions via secreted and contact-mediated signals play a
critical role in these pathways. In order to study these
dynamic small-scale processes, herein is disclosed a micro-
T
mechanical platform to control microscale cell organization
so that cell patterns can be reconfigured dynamically. In one
embodiment, this tool has been employed to deconstruct the
mechanisms by which liver-specific function is maintained
5 in hepatocytes upon co-cultivation with stromal support
cells. Specifically, the relative roles of cell contact and
short-range soluble signals, duration of contact, and the
possibility of bi-directional signaling were examined. In
another embodiment, this tool has been used to investigated
io microenvironmental regulation of the sinusoidal endothelial
cell phenotype.
In certain embodiments, the inventive device consists of
two parts that can be locked together either to allow cell-cell
contact across the two parts or to separate the cells by a
15 uniform gap. Switching between these two states is actuated
simply by pushing the parts manually using tweezers; no
micromanipulation machinery is necessary. Micron-scale
precision is possible due to a 20:1 mechanical transmission
ratio and microfabricated snap locks, both of which are
20 monolithically incorporated into the silicon structure. In
certain embodiments, the entire device is fabricated in a
simple single-mask process using through-wafer deep reac-
tive ion etching. In certain embodiments, to provide a
surface compatible with cell culture, the surface is coated
25 with a layer of polystyrene and plasma-treated, providing a
standard tissue-culture surface. In other embodiments, the
device is fabricated from silicon. In other embodiments, the
device is fabricated from polyurethane. In certain embodi-
ments, the parts can be anchored to a frame while being
30 etched, and then released with a dicing saw or the like.
Herein are disclosed devices and methods designed to
enable one precisely to control tissue organization and
composition by leveraging tools from the field of micro-
electromechanical systems (MEMS), which offers precise
35 physical manipulation at a length scale comparable to that of
many biological processes. In certain embodiments, cells are
grown on an array of micromachined plates that are physi-
cally rearranged in order to change the spatial organization
of the culture. This will be referred to as micromechanical
4o reconfigurable culture (µRC). Cells remain attached to the
substrate throughout the repositioning process (Chen, C. S.,
Mrksich, M., Huang, S., Whitesides, G. M. & Ingber, D. E.
(1997) Science 276, 1425-1428; and McBeath, R., Pirone,
D. M., Nelson, C. M., Bhadriraju, K. & Chen, C. S. (2004)
45 Dev Cell 6, 483-95). Using µRC, dynamic regulation of
cell-cell interactions via direct manipulation of cell posi-
tioning has been demonstrated. Specifically, cell-cell contact
between different cell populations was regulated by posi-
tioning plates together or apart. By imposing a small micron-
50 scale separation between the plates, cell-cell contact can be
abrogated while soluble signaling is maintained. By employ-
ing larger separation distances, the extent of soluble signal-
ing can also be modulated. In addition, by removing a plate
and replacing it, one population of cells can be exchanged
55 for another in a modular fashion. Thus, this MEMS-based
approach provides dynamic control of both tissue organiza-
tion and composition.
Micromechanical Reconfigurable Culture Devices (µRC).
In certain embodiments, the micromechanical reconfigu-
6o rable culture devices of the invention consist of two or more
components that can be moved with respect to each other. In
certain embodiments, the devices of the invention are a
single piece, parts of which can be moved with respect to
each other. In certain embodiments, the components of the
65 device are shaped as flat plates or curved surfaces.
In certain embodiments, the components of the device can
be mounted on a positioning system which allows their
US 9,611,453 B2
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position, relative to each other, to be varied. In another
embodiment, in order to connect the two (or more) compo-
nent, one or more flexures may be used. As used herein, a
"flexure" is a flexible mechanical member used to connect
two separate components. A properly designed flexure is
extremely stiff in every direction except the direction of
motion. In certain embodiments, the flexures of the inven-
tion may be used as a hinge to guide the linear motion of two
or more of the components.
In certain embodiments, at least one of the components of
the device will have two substantially-parallel arm flexures
protruding from the main body of the component. In certain
embodiments, these arm flexures each include a distal catch
(or latch) with corresponds to slot (or notch) on a separate
component. An example of the use of flexures in the
invention is the integrated snap-lock mechanism shown in
FIG. 1E. As shown in FIG. 1E, in certain embodiments, the
matching V-shaped latches and notches are self-centering,
allowing the parts to be accurately and reproducibly posi-
tioned using only tweezers, without the need for micro-
scopic visualization or micromanipulation machinery. In
certain embodiments, the extent of finger separation in the
gap mode can be tuned via notch positioning; multiple sets
of notches could also be employed to allow variable spacing.
In certain embodiments, the snap-lock mechanism can
consist of more than one set of snaps and slots, giving
multiple points of constraint (e.g., leading to greater stabil-
ity). In certain embodiments, there are two snaps and two
sets of locks.
Further, the alignment of components of the invention
may be facilitated by features on one component which fit
into features of another component, thereby constraining the
mechanical positioning of the components. For example, in
certain embodiments, these features are implemented as
teeth in a comb pattern. In certain embodiments, the con-
tacting surfaces are angled with respect to the direction of
motion so that the changes in separation between parts is less
than the total amount of motion. In such embodiments, finer
positioning accuracy can be obtained, particularly when
using coarse actualization methods, such as manual pushing.
In certain embodiments, the µRC device consists of two
components with interlocking comb fingers and an inte-
grated snap-lock mechanism (as discussed above). The
components can be fully separated, locked together with the
fingers in contact, or locked together with a fixed gap
between the comb fingers (FIG. 1A). These configurations
are referred to as the separated, contact, and gap modes.
Cells are cultured on the top surface of the fingers (FIGS. 1B
and 1C). In certain embodiments, each the fingers of each
component can contain one type of cell, wherein the cells on
the first component are not the same as the cells on the
second component. In other words, each component has a
"pure" population of cells. In other embodiments, the cells
cultured on any given finger can be a mixed population of
more than one cell type.
In certain embodiments, parts can be separated into indi-
vidual wells of a multi-well plate for coating of extracellular
matrix proteins and seeding of cells, so as to avoid cross-
contamination. Following cell attachment, the two parts can
be assembled in a fresh well (FIG. 1D), where cell culture
and functional assays can be performed in a standard man-
ner. The actuation strategy to switch between modes was
designed for simplicity and compatibility with standard
aseptic cell-culture technique.
In certain embodiments, the entire µRC device is fabri-
cated in a simple single-mask process using through-wafer
deep reactive ion etching (see intermediates of this process
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in FIG. 7). See, for example: Ayon, A. A., Braff, R., Lin, C.
C., Sawin, H. H. & Schmidt, M. A. (1999) Journal of the
Electrochemical Society 146, 339-349; and Knobloch, A. 7.,
Wasilik, M., Fernandez-Pello, C. & Pisano, A. P. (2003) in
5 2003 ASME International Mechanical Engineering Con-
gress (American Society of Mechanical Engineers, New
York, N.Y. 10016-5990, United States, Washington, D.C.,
United States), Vol. 5, pp. 115-123. In certain embodiments,
a silicon wafer can be coated with a micrometer thick layer
io of silicon dioxide. After which, a layer of thick photoresist
can be spin-coated onto the coated silicon wafer, patterned
using a chrome mask and contact alignment, and developed.
The patterned wafer, or device wafer, can then be attached
to a handle wafer using a photoresist bond. After etching
15 through the oxide layer, deep reactive ion etching can be
used to etch through the entire device wafer. The parts can
then be released in acetone and cleaned in "Piranha" (chro-
mic acid-containing) solution.
As mentioned above, to provide the necessary mechanical
20 precision, silicon parts can be fabricated in a single mask,
through-wafer, deep reactive ion etching process. In the
exemplification provided herein, a separation of 6µm or less
was measured in the contact mode, and 79±1 µm in the gap
mode. Using fluorescent membrane dyes and microscopy,
25 cells on opposing fingers were shown to form intimate
contacts in contact mode (FIG. 213). In addition, contami-
nation of cells between adjacent fingers after 1S hours of
contact was minimal (FIG. 2C).
In certain embodiments, the silicon parts of the µRC
3o device are modified to aid in the culture of different cell
types. In certain embodiment, the silicon parts of the device
spincoated with polystyrene, resulting in a surface compa-
rable to tissue culture plastic. This can aid, for example, in
the binding of fibroblasts; poor adhesion was of fibroblast
35 cells on unmodified silicon surfaces has been observed (data
not shown). In certain embodiments, collagen is adsorbed
onto the silicon parts of the device. This can aid, for
example, in the binding of hepatocytes.
In certain embodiments, the inventive µRC device could
40 include embedded microfluidics and sensors for local deliv-
ery of soluble factors and in situ monitoring (Papageorgiou,
D. P., Shore, S. E., Bledsoe Jr, S. C. & Wise, K. D. (2006)
Journal of Microelectromechanical Systems 15, 1025-1033),
and/or integrated actuation for heterogeneous mechanical
45 control of array elements.
In certain embodiments, the µRC device is fabricated
from an optically transparent material. In certain embodi-
ments, the µRC device is fabricated from an optically
translucent material. Transparent and translucent µRC
5o devices could be used with inverted biological microscopes.
As used herein, transparent materials can be seen through;
that is, they allow clear images to pass. Translucent mate-
rials allow light to pass through them only diffusely, that is,
the material distorts the image. In certain embodiments, the
55 µRC device is fabricated from an optically transparent or
optically translucent material selected from the group con-
sisting of glasses and plastics.
In certain embodiments, the µRC device comprises more
than two interlocking pieces. In certain embodiments, the
60 µRC device comprises more three interlocking pieces. In
certain embodiments, the µRC device comprises four inter-
locking pieces. In certain embodiments, the µRC device
comprises more than four interlocking pieces.
Developmental Biology: Stem Cells/Morphogens. Cell-
65 cell interactions play a critical role in driving differentiation
during development. Stem cells are defined as cells that are
capable of a differentiation into many other differentiated
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cell types. Embryonic stem cells are stem cells from
embryos which are capable of differentiation into most, if
not all, of the differentiated cell types of a mature body. Stem
cells are referred to as pluripotent, which describes this
capability of differentiating into many cell types. A category 5
of pluripotent stem cell of high interest to the research
community is the human embryonic stem cell, abbreviated
here as hES cell, which is an embryonic stem cell derived
from a human embryonic source. Human embryonic stem
cells are of great scientific interest because they are capable io
of indefinite proliferation in culture and are thus capable, at
least in principle, of supplying cells and tissues for replace-
ment of failing or defective human tissue. The existence in
culture of human embryonic stem cells offers the potential of
unlimited amounts of human cells and tissues for use in a 15
variety of therapeutic protocols to assist in human health. In
the future human embryonic stem cells may be proliferated
and directed to differentiate into specific lineages so as to
develop differentiated cells or tissues which can be trans-
planted into human bodies for therapeutic purposes. 20
One of most significant features of human embryonic
stem cells is the attribute of being capable of self-renewal.
By that, it is meant that the hES cells are capable of
proliferating into multiple progeny stem cells, each of which
seems to have the full potential of its ancestor cell. In other 25
words, the progeny are renewed to have all the develop-
mental and proliferative capacity of the parental cell. This
attribute, combined with the pluripotency, are the traits that
make hES cells candidates for many potential uses, since, in
theory, hES cells can be reproduced indefinitely and in large 30
numbers and then induced to become any cell type in the
human body. The ability to self-renew appears closely linked
to the attribute of being undifferentiated in the sense that at
least given present knowledge, only undifferentiated hES
cells are capable of indefinite self-renewal; i.e., as soon as 35
the cells differentiate, the self-renewal capability is lost.
During the course of development, cells of many tissues
differentiate according to the positional information that is
set by the concentration gradients of morphogens. Morpho-
gens are signaling molecules that emanate from a restricted 40
region of a tissue and spread away from their source to form
a concentration gradient. As the fate of each cell in the field
depends on the concentration of the morphogen signal, the
gradient prefigures the pattern of development. Thus, micro-
mechanical reconfigurable culture (µRC) is an ideal way to 45
study morphogens and the cells they effect (e.g., stem cells).
As described above, a morphogen is a substance govern-
ing the pattern of tissue development and, in particular, the
positions of the various specialized cell types within a tissue.
It spreads from a localized source and forms a concentration 50
gradient across a developing tissue. Well-known morpho-
gens include: Decapentaplegic/Transforming growth factor
beta, Hedgehog/Sonic Hedgehog, Wingless/Wnt, Epidermal
growth factor, and Fibroblast growth factor. Morphogens are
defined conceptually, not chemically, so simple chemicals 55
such as retinoic acid may also act as morphogens.
For example, bone morphogenesis is induced by bone
morphogenetic proteins (BMPs). BMPs play a role in pat-
tern formation, cell differentiation, maintenance and regen-
eration of tissues. BMPs are pleiotropic and act on chemo- 60
taxis, mitosis and differentiation of progenitor stem cells.
There are nearly twenty BMPs in the human genome. BMPs
have actions beyond bone in development of teeth, heart,
kidney, eye, skin, and brain. Thus, BMPs may be called body
morphogenetic proteins. Stem cells are primordial cells with 65
unlimited replicative potential and can be programmed by
morphogens such as BMPs.
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Developmental Biology: Cytokines/Cytokine Receptors.
Cytokines are small secreted proteins which mediate and
regulate immunity, inflammation, and hematopoiesis. They
often are produced de novo in response to an immune
stimulus. They generally (although not always) act over
short distances and short time spans and at very low con-
centration. They act by binding to specific membrane recep-
tors, which then signal the cell via second messengers, often
tyrosine kinases, to alter its behavior (gene expression).
Responses to cytokines include increasing or decreasing
expression of membrane proteins (including cytokine recep-
tors), proliferation, and secretion of effector molecules.
Thus, micromechanical reconfigurable culture (µRC) is an
ideal way to study cytokines and their receptors.
Cytokine is a general name; other names include lym-
phokine (cytokines made by lymphocytes), monokine (cy-
tokines made by monocytes), chemokine (cytokines with
chemotactic activities), and interleukin (cytokines made by
one leukocyte and acting on other leukocytes). Cytokines
may act on the cells that secrete them (autocrine action), on
nearby cells (paracrine action), or in some instances on
distant cells (endocrine action). As used herein, cytokine
encompasses all of these.
It is common for different cell types to secrete the same
cytokine or for a single cytokine to act on several different
cell types (pleiotropy; see FIGS. 8a and 8b). Cytokines are
redundant in their activity, meaning similar functions can be
stimulated by different cytokines. Cytokines are often pro-
duced in a cascade, as one cytokine stimulates its target cells
to make additional cytokines. Cytokines can also act syn-
ergistically (two or more cytokines acting together) or
antagonistically (cytokines causing opposing activities).
Their short half life, low plasma concentrations, pleiot-
ropy, and redundancy all complicated the isolation and
characterization of cytokines. Searches for new cytokines is
now often conducted at the DNA level, identifying genes
similar to known cytokine genes. However, micromechani-
cal reconfigurable culture (µRC) might allow an alternative
way in which to identify new cytokines, as well as study the
effects of known cytokines.
The largest group of cytokines stimulates immune cell
proliferation and differentiation. This group includes Inter-
leukin 1 (IL-1), which activates T cells; IL-2, which stimu-
lates proliferation of antigen-activated T and B cells; IL-4,
IL-5, and IL-6, which stimulate proliferation and differen-
tiation of B cells; Interferon gamma (IFNg), which activates
macrophages; and IL-3, IL-7 and Granulocyte Monocyte
Colony-Stimulating Factor (GM-CSF), which stimulate
hematopoiesis.
Other groups of cytokines include interferons and
chemokines. Interferons IFNa and IFNb inhibit virus repli-
cation in infected cells, while IFNg also stimulates antigen-
presenting cell MHC expression. Chemokines attract leuko-
cytes to infection sites. Chemokines have conserved
cysteine residues that allow them to be assigned to four
groups. The groups, with representative chemokines, are
C-C chemokines (RANTES, MCP-1, MIP-1 a, and MIP-lb),
C-X-C chemokines (IL-8), C chemokines (Lymphotactin),
and CXXXC chemokines (Fractalkine). Some cytokines are
predominantly inhibitory. For example, IL-10 and IL-13
inhibit inflammatory cytokine production by macrophages.
Helper T cells have two important functions: to stimulate
cellular immunity and inflammation, and to stimulate B cells
to produce antibody. Two functionally distinct subsets of T
cells secrete cytokines which promote these different activi-
ties. Thl cells produce IL-2, IFNg, and TNFP, which acti-
vate Tc and macrophages to stimulate cellular immunity and
US 9,611,453 B2
11
inflammation. Thl cells also secrete IL-3 and GM-CSF to
stimulate the bone marrow to produce more leukocytes. Th2
cells secrete IL-4, IL-5, IL-6, and IL-10, which stimulate
antibody production by B cells.
T cells are initially activated as Th0 cells, which produce
IL-2, IL-4 and IFNg. The nearby cytokine environment then
influences differentiation into Thl or Th2 cells. IL-4 stimu-
lates Th2 activity and suppresses Thl activity, while IL-12
promotes Thl activities. Thl and Th2 cytokines are antago-
nistic in activity. Thl cytokine IFNg inhibits proliferation of
Th2 cells, while IFNg and IL-2 stimulate B cells to secrete
I9G2a and inhibit secretion of IgGI and IgE. Th2 cytokine
IL-10 inhibits Thl secretion of IFNg and IL-2; it also
suppresses Class II MHC expression and production of
bacterial killing molecules and inflammatory cytokines by
macrophages. IL-4 stimulates B cells to secrete IgE and
IgGI. The balance between Thl and Th2 activity may steer
the immune response in the direction of cell-mediated or
Immoral immunity.
Cytokines act on their target cells by binding specific
membrane receptors. The receptors and their corresponding
cytokines have been divided into several families based on
their structure and activities. Hematopoietin family recep-
tors are dimers or trimers with conserved cysteines in their
extracellular domains and a conserved Trp-Ser-X-Trp-Ser
sequence. Examples are receptors for IL-2 through IL-7 and
GM-CSF. Interferon family receptors have the conserved
cysteine residues but not the Trp-Ser-X-Trp-Ser sequence,
and include the receptors for IFNg, IFNP, and IFNg. Tumor
Necrosis Factor family receptors have four extracellular
domains; they include receptors for soluble TNFoL and
TNFP as well as membrane-bound CD40 (important for B
cell and macrophage activation) and Fas (which signals the
cell to undergo apoptosis). Chemokine family receptors
have seven transmembrane helices and interact with G
protein. This family includes receptors for IL-8, MIP-1 and
RANTES. Chemokine receptors CCR5 and CXCR4 are
used by HIV to preferentially enter either macrophages or T
cells.
Hematopoietin cytokine receptors are the best character-
ized. They generally have two subunits, one cytokine-
specific and one signal transducing. An example is the
GM-CSF subfamily, where a unique a subunit specifically
binds either GM-CSF, IL-3, or IL-5 with low aflinity and a
shared R subunit signal transducer also increases cytokine-
binding affinity. Cytokine binding promotes dimerization of
the a and R subunits, which then associate with cytoplasmic
tyrosine kinases to phosphorylate proteins which activate
mRNA transcription. GM-CSF and IL-3 act on hematopoi-
etic stem cells and progenitor cells and activate monocytes.
With IL-5, they also stimulate eosinophil proliferation and
basophil degranulation. All three receptors phosphorylate
the same cytoplasmic protein. Antagonistic GM-CSF and
IL-3 activities can be explained by their competition for
limited amounts of R subunit.
The IL-2R subfamily of receptors for IL-2, IL-4, IL-7 ,
IL-9, and IL-15 have a common signal-transducing g chain.
Each has a unique cytokine-specific a chain. IL-2 and IL-15
are trimers, and share an IL-2R R chain. Monomeric IL-2R
a has low affinity for IL-2, dimeric IL-2R bg has intenne-
diate affinity, and trimeric IL-2R abg binds IL-2 with high
affinity. IL-2R a chain (Tac) is expressed by activated but
not resting T cells. Resting T cells and NK cells constitu-
tively express low numbers of IL-2py. Antigen activation
stimulates T cell expression of high affinity IL-2R trimers as
well as secretion of IL-2, allowing autocrine stimulation of
T cell proliferation in an antigen-specific manner. Antigen
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specificity of the immune response is also maintained by the
close proximity of antigen-presenting B cells and macro-
phages with their helper T cells, so that cytokines are
secreted in the direction of and close to the membrane of the
5 target cell. X-linked severe combined immunodeficiency
(X-scid) is caused by a defect in IL-2R family y chain, which
results in loss of activity from this family of cytokines.
Cytokine activity can be blocked by antagonists, mol-
ecules which bind cytokines or their receptors. IL-1 has a
io specific antagonist that blocks binding of IL-1 a and IL-1(3 to
their receptor. During immune responses, fragments of
membrane receptors may be shed and then compete for
cytokine binding. Microbes also influence cytokine activi-
ties. For example, Vaccinia virus (Smallpox and Cowpox)
15 encodes soluble molecules which bind IFNg, while Epstein-
Barr virus (Infectious Mononucleosis) encodes a molecule
homologous to IL-10 that suppresses immune function in the
host.
The TNF receptor family molecules CD40 and Fas bind
20 cell surface ligands on effector T cells: CD40L and FasL.
CD40 is expressed on B cell and macrophage plasma
membranes. T cell CD40L binding to B cell CD40 stimu-
lates B cell proliferation and isotype switching. T cell
CD40L binding to macrophage CD40 stimulates macro-
25 phages to secrete TNFa and become much more sensitive to
IFNg. T cell FasL binding to Fas leads to the activation of
caspase proteases that initiate apoptosis of the cell express-
ing membrane Fas. Activated lymphocytes express Fas, so
that FasL-positive Tc cells can regulate the immune response
3o by eliminating activated cells. An immune deficiency dis-
ease linked to expression of a mutant Fas is characterized by
over-proliferation of lymphocytes.
Cancer Biology. Interactions between a tumor and its
surrounding stroma are known to play an important role in
35 determining the progression of certain cancers. Cancers are
classified by the type of cell that resembles the tumor and,
therefore, the tissue presumed to be the origin of the tumor.
The following general categories are usually accepted: car-
cinoma, lymphomas, leukemias, sarcomas, mesotheliomas,
40 gliomas, germinomas, and choriocarcinomas. Carcinomas
are malignant tumors derived from epithelial cells. This
group represent the most common cancers, including the
common forms of breast, prostate, lung and colon cancer.
Lymphomas and leukemias are malignant tumors derived
45 from blood and bone marrow cells. Sarcomas are malignant
tumors derived from connective tissue, or mesenchymal
cells. Mesotheliomas are tumors derived from the mesothe-
lial cells lining the peritoneum and the pleura. Gliomas are
tumors derived from glia, the most common type of brain
50 cell. Genninomas are tumors derived from germ cells,
normally found in the testicle and ovary. Choriocarcinomas
are malignant tumors derived from the placenta.
RNAi. In certain embodiments of the invention, RNA
interference (RNAi) techniques can be used in conjunction
55 with method which employ the micromechanical reconfigu-
rable culture devices of the invention. RNAi is a technique
widely used to down-regulate the mRNA level of a specific
gene. Small interfering RNAs (siRNAs) or small hairpin
RNAs (shRNAs) are composed of a 22 nt-double strand
6o RNA sequence completely homologous to an unique target
gene. ShRNAs are generally produced by RNA polymerase
II or III-based vectors while siRNA can be obtained from
biotechnology companies. The siRNA or shRNA-expressing
vectors are transfected into cell lines with classical lipotrans-
65 fectants. The homology of sequence with a specific target
gene allows formation of a complex comprising one strand
of the shRNA or siRNA hybridized with the mRNA target
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and the RISC (RNAi-induced silencing complex) proteins in
the cytoplasm. RISC then degrades the mRNA, which
cannot be translated. The whole process leads to the specific
downregulation of the RNA of the corresponding gene
within 24-72 hours.
Microenvironmental Regulation of Sinusoidal Endothe-
lial Cell Phenotypes. Liver Sinusoidal Endothelial Cells
(LSEC) are distinct from other vascular endothelial cells
(EC) present in other tissues in their structural and func-
tional phenotypic characteristics. For example, in contrast to
other EC, LSEC display fenestrations, have low or absent
expression of PECAM-1, and in rat tissue, they distinctively
express the specific surface marker SE-1. Interestingly, these
phenotypic characteristics are lost over time when LSEC are
placed in culture. Since phenotypic maintenance is critical to
the development of accurate in vitro liver models and tissue
engineered constructs, by using the devices and methods
described herein the one can examine effect of various
microenvironmental stimuli, such as tailoring of the extra-
cellular matrix (ECM) and co-culture with supportive cell
types, on LSEC phenotype.
For example, immunohistochemistry and Western blot-
ting were used to characterize expression of the specific EC
markers RECA, SE-1, PECAM and AcLDL in isolated
primary rat LSECs were cultured under the following con-
ditions: a) on the different ECM proteins including, Colla-
gen-I, Fibronectin, Laminin, and Collagen-IV; b) with vari-
ous combinations of supportive cells, using the
micromechanical reconfigurable culture method described
herein to enable tracking of individual cell types, separation
into pure populations for analysis, and deconvolution of
contact-mediated versus soluble signals; and c) in the pres-
ence of the tyrosine phosphatase inhibitor, orthovanadate
(OV). Results of these studies are shown in FIGS. 9, 10 and
11.
Interestingly, using the methods described above, a
decrease in the expression of SE-1 and increase expression
of PECAM-1 was observed when LSEC were placed in
culture; in addition, an effect of specific ECM components
on the levels of expression of SE-1 was also observed,
suggesting a role of ECM in modulating LSEC phenotype.
Significantly, SE-1 expression could be maintained for lon-
ger periods through co-culture up to 14 days in the optimal
configuration involving co-cultivation with both hepatocytes
and fibroblasts. The data also suggest that direct contact
between LSECs and support cells is not necessary. To begin
to gain a mechanistic insight into these observations, the role
of tyrosine phosphorylation of cellular proteins in maintain-
ing LSEC phenotype was investigated, since it has previ-
ously demonstrated that OV inhibited LSEC apoptosis (Fu-
jimoto, H. et al. (2006) Am JPathol 168, 1086-1096). It was
found that SE-1 expression was strongly maintaining at day
3 when they were cultured in the presence of OV, suggesting
that a decrease in protein phosphorylation is involved also in
the loss of the phenotype. In addition, the co-culture of
LSEC with hepatocytes or fibroblast-stabilized hepatocytes
induced LSEC proliferation as well as the activation of the
transcription factor STAT-1.
Collectively, the experiments described above led to the
identification of novel microenvironmental regulators of the
LSEC phenotype, which may be important for the develop-
ment of better in vitro models the study of liver biology and
tissue engineering constructs.
Selected Applications. In one embodiment, the inventive
dynamic platform disclosed herein was used to study cell-
cell interactions between hepatocytes and stromal cells in
co-culture. As with many other cell types, interaction of
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epithelia with supportive stroma or ` feeder layers' promotes
tissue-specific gene expression in vitro. In the case of
primary hepatocytes, co-cultivation of hepatocytes with
many different mesenchymal cell types (endothelia, fibro-
5 blasts, etc.) promotes retention of hepatocyte viability and
liver-specific functions that are otherwise rapidly lost in
vitro (Bhatia, S. N., Balis, U. 7., Yarmush, M. L. & Toner,
M. (1999) Faseb J 13, 1883-900). This robust ` co-culture'
phenomena, though poorly understood, has wide-ranging
io applications in both therapeutic and diagnostic applications
of engineered liver tissue (Tilles, A. W., Baskaran, H., Roy,
P., Yarmush, M. L. & Toner, M. (2001) Biotechnol Bioeng
73, 379-89; Allen, J. W., Khetani, S. R. & Bhatia, S. N.
(2005) Toxicol Sci 84, 110-9; and Guillouzo, A. (1998)
15 Environ Health Perspect 106 Suppl 2, 511-32). Using both
conventional techniques and micropatterning approaches, it
has previously been found that the degree of interaction
between the two cell types (`heterotypic interaction') modu-
lated the amount of liver-specific function retained in vitro
20 (Bhatia, S. N., Balis, U. 7., Yarmush, M. L. & Toner, M.
(1999) Faseb J 13, 1883-900; and Guguen-Guillouzo, C. &
Guillouzo, A. (1983) Mol Cell Biochem 53-54, 35-56).
These findings suggested an important role for proximity
between the two cell types in the rescue of hepatocyte
25 phenotype; however, the relative role of contact-mediated
versus soluble signals, the dynamics of interaction, and the
potential for reciprocal signaling had not been established.
Hence, in order to explore this system using the µRC
substrates, primary rat hepatocytes and Swiss 3T3 murine
30 fibroblasts were cultured on opposing combs. Hepatocyte
morphology and viability were assessed microscopically
and albumin production was measured as a quantitative
marker of liver-specific function. Comparison of cultures in
the contact, gap, and separated modes demonstrated that
35 contact was necessary for maintenance of liver-specific
function (FIG. 3A). Even in the gap mode, which corre-
sponded to only an 80-µm separation between the two cell
populations, hepatocyte function declined at a rate similar to
that of hepatocytes cultured alone. Next, dynamic experi-
40 ments in which cells were repositioned following 18 h of
contact were conducted. Here, transient contact alone
proved insufficient to rescue the hepatocyte phenotype, and
liver-specific functions rapidly declined. In contrast, tran-
sient contact followed by sustained culture in the gap mode
45 provided complete rescue of liver-specific function (FIG.
313). These observations thus imply a necessary role both for
heterotypic contact and for soluble factors that diffuse across
the gap.
Notably, it would appear that contact was required only
50 initially, whereas soluble interactions were required for the
duration of the experiment. This finding raised the possibil-
ity that reciprocal interactions i.e., sustained alterations in
fibroblast function as a result of hepatocyte contact might
play a role. In order to test this possibility, the ` modular'
55 nature of the µRC platform was explored. Co-cultures were
conducted in contact mode for 18 h as before; however, the
fibroblasts were then replaced with naive fibroblasts (no
exposure to heterotypic contact) in gap mode. Under these
conditions, paracrine signals provided by naive fibroblasts
60 were still sufficient to sustain hepatic functions (FIG. 3C).
Conversely, if naive hepatocytes were substituted, hepatic
function deteriorated. Hence, the data are consistent with
constitutive expression of critical soluble factors by fibro-
blasts independent of hepatocyte interaction rather than
65 supporting a role for reciprocal cell-cell interaction.
To investigate the importance of cell proximity, device
pairs were separated into separate wells following 18 h of
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initial contact. Conditioned media was then transferred from
the fibroblast well to the hepatocyte well every two days.
However, hepatic function was not maintained (FIG. 4A),
underscoring the importance of close positioning in the gap
configuration. Further, microscopic examination of co-cul-
tures yielded a striking observation: in cultures stabilized via
transient contact followed by gap mode, hepatocytes
towards the rear of each comb finger lost viability over the
course of two weeks (FIG. 413). Hepatocyte-fibroblast dis-
tance is greater in this region compared to the rest of the
comb finger due to the geometry of the device in the gap
configuration (FIG. 1A, inset). Quantifying viability using a
fluorescent membrane integrity dye yielded a characteristic
length of decay in viability of approximately 325 µm (FIG.
4C). It was demonstrated through finite element modeling
that diffusion of a rapidly decaying (on the order of hours)
or rapidly consumed (comparable to rate of production)
soluble factor could produce concentration profiles similar
to the survival pattern of FIG. 4B (FEM Diffusion Model).
These data suggest that the fibroblast-derived soluble signals
critical for rescue of the hepatocyte phenotype and viability
are effective over a very limited range, on the order of only
10 cell diameters.
Preservation of hepatocyte viability and liver-specific
functions in co-culture appears to depend on an initial
contact-mediated signal followed by a sustained short-range
soluble signal from fibroblasts to hepatocytes (FIG. 5). It is
not clear whether the contact-mediated signal is junctional in
nature (hepatocytes and 3T3 fibroblasts do not express
similar cadherin or connexin subtypes) or due to cell-
associated matrix molecules. It is also unknown why only
transient contact is required. One possibility is that transient
contact triggers an irreversible signaling pathway. Alterna-
tively, the contaminating cells that remain after separation
(FIG. 2C) may play a role in the response. This seems
unlikely since hepatic function could not be maintained in
gap mode without initial contact, even when low numbers of
fibroblasts were doped onto the hepatocyte fingers (data not
shown). A third possibility is that fibroblasts secrete critical
extracellular matrix components onto the hepatocyte fingers
during the transient contact period that help to sustain
function thereafter. Regardless, these data point to the pos-
sibility that hepatocytes could be preconditioned and sub-
sequently sustained without supportive stromal cells, a find-
ing with significant practical implications for the therapeutic
and diagnostic applications of hepatocytes. Notably, only the
peripheral hepatocytes can directly contact fibroblasts, yet
the entire population is affected. This finding is consistent
with previous reports but the precise mechanism has not yet
been established Finally, the possible reasons that soluble
signals are effective over very limited distances include: that
the critical factors are highly labile, are active at relatively
high local concentration, or are rapidly sequestered extra-
cellularly via binding to extracellular matrix proteins.
As the example above suggests, µRC may be utilized to
execute a number of previously inaccessible experiments.
The disclosure herein establishes that it is possible to
decouple contact-mediated and soluble signals, dynamically
modulate both contact-mediated and soluble cell-cell sig-
naling, examine the reversibility of a pathway upon removal
of the triggering signal, test for the presence of reciprocal
cell-cell signaling, and measure the effective range of
soluble signals. In other words, the disclosure herein estab-
lishes that micromechanical culture substrates are a robust
and generalizable tool. Since, in certain embodiments, the
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device surface is comparable to tissue culture plastic, it
should be readily adapted to a variety of cell types and
molecular techniques.
For example, compatibility with liver progenitors, sinu-
5 soidal endothelial cells, and bone marrow stromal cells, as
well as transfection of siRNA into individual cell popula-
tions has been demonstrated (FIG. 6). This methodology
will find utility in the investigation of cellular niches
(Moore, K. A. & Lemischka, I. R. (2006) Science 311,
io 1880-1885), in the dissection of developmental processes
(Lemaigre, F. & Zaret, K. S. (2004) Curr Opin Genet Dev
14, 582-90), and in the study of disease progression in
particular in tissues where stromal interactions are thought
to play a role (e.g., tumorigenesis; Zigrino, P., Loffek, S. &
15 Mauch, C. (2005) Biochimie 87, 321-328).
Selected Methods of the Invention. The following meth-
ods illustrate different aspects and embodiments of the
present invention, and are not intended to limit the scope of
the invention.
20 One aspect of the invention relates to a method compris-
ing the steps of culturing at least one cell of a first type on
a first component; culturing at least one cell of a second type
on a second component; and placing the first component at
a distance from or in contact with the second component for
25 a time; thereby co-culturing the at least one cell of a first type
and the at least one cell of a second type.
As discussed above, cell-cell interactions play a critical
role in driving cell differentiation during development. The
reconfigurable substrates of the invention could be used to
30 simulate these processes in vitro. For example, stem cells or
progenitor cells can be driven down a specific differentiation
pathway by bringing them into contact with a series of
different cell types. Therefore, one aspect of the invention
relates to a method of stimulating cell differentiation com-
35 prising the steps of:
culturing a plurality of cells of a first type on a first
component, wherein the cells of a first type are stem cells or
progenitor cells;
culturing a plurality of cells of a second type on a second
40 component, wherein the cells of a second type secrete a
differentiation-inducing signal; and
placing the first component at a distance from or in
contact with the second component for a time.
In certain embodiments, the present invention relates to
45 the aforementioned method and any of the attendant limi-
tations, further comprising the step of determining if the
cells of a first type have differentiated.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
50 tations, wherein the cells of a first type are mammalian cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are human cells.
In certain embodiments, the present invention relates to
55 the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are early embryonic
stem cells, blastocyst embryonic stem cells, fetal stem cells,
umbilical cord stem cells, or adult stem cells.
In certain embodiments, the present invention relates to
60 the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are adult stem cells
isolated from nerve cells, blood cells, muscle cells, skin
cells, or bone cells.
In certain embodiments, the present invention relates to
65 the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are human embryonic
stem cells.
US 9,611,453 B2
17
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are mammalian
cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are human cells.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a second type secrete morpho-
gens.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a second type secrete morpho-
gens selected from the group consisting of decapentaplegic/
transforming growth factor beta, hedgehog/sonic hedgehog,
wingless/wnt, epidermal growth factor, and fibroblast
growth factor.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a second type secrete morpho-
gens selected from the group consisting of human OP-1,
mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1,
BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3, BMP5, and
BMP6.
Further, the effects of soluble factors on any cell type, not
just stem-cells, may be studied using the devices of the
invention. Therefore, another aspect of the invention relates
to a method of exposing cells to cytokines comprising the
steps of:
culturing a plurality of cells of a first type on a first
component, wherein the cells of a first type are target cells
comprising a receptor;
culturing a plurality of cells of a second type on a second
component, wherein the cells of a second type secrete
soluble signal; and
placing the first component at a distance from or in
contact with the second component for a time.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
tations, further comprising the step of determining the effect
of soluble signal exposure on the cells of a first type.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are mammalian cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are human cells.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a first type comprise receptors
for a member of the VEGF family, VEGF-D, a member of
the MIP family, MIP-ly, ceruloplasmin, nitric oxide, gases,
or growth factors.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a first type comprise DLK,
Dlk-1, a cahedrins, or T-cahedrin.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are mammalian
cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are human cells.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
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tations, wherein the cells of a second type secrete
hematopoietins, interferons, tumor necrosis factors,
chemokines, or a combination thereof.
In certain embodiments, the present invention relates to
5 the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a second type secrete a member
of the VEGF family, VEGF-D, a member of the MIP family,
MIP-ly, ceruloplasmin, nitric oxide, gases, or growth factors
In particular, the inductive effect of cytokine gradients can
io be studied by varying the separation between inducer and
target cell populations. Therefore, another aspect of the
invention relates to a method of exposing cells to cytokines
comprising the steps of:
culturing a plurality of cells of a first type on a first
15 component, wherein the cells of a first type are target cells
comprising a cytokine receptor;
culturing a plurality of cells of a second type on a second
component, wherein the cells of a second type secrete a
cytokine; and
20 placing the first component at a distance from or in
contact with the second component for a time.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
tations, further comprising the step of determining the effect
25 of cytokine exposure on the cells of a first type.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are mammalian cells.
In certain embodiments, the present invention relates to
30 the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are human cells.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a first type comprise cytokine
35 receptors selected from the group consisting of hematopoi-
etin family receptors, interferon family receptors, tumor
necrosis factor family receptors, and chemokine family
receptors.
In certain embodiments, the present invention relates to
40 the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a first type comprise cytokine
receptors selected from the group consisting of receptors for
IL-la, IL-1(3, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,
IL-12, IL-15, GM-CSF, IFN-a, IFN-(3, IFN-y, TNF-a, TNF-
45 (3, CD40, Fas, MIP-la, MIP-1(3, RANTES, CCR5, and
CXCR4.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are mammalian
50 cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are human cells.
In certain embodiments, the present invention relates to
55 the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a second type secrete
hematopoietins, interferons, tumor necrosis factors,
chemokines, or a combination thereof.
In certain embodiments, the present invention relates to
60 the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a second type secrete IL-la,
IL-1(3, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-12,
IL-15, GM-CSF, IFN-a, IFN-(3, IFN-y, TNF-a, TNF-(3,
CD40, Fas, MIP-la, MIP-1(3, RANTES, CCR5, or CXCR4.
65 Interactions between a tumor and its surrounding stroma
are known to play an important role in determining the
progression of certain types of cancer; reconfigurable sub-
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strates may be used to study these interactions. For example,
tumor cells can be switched from co-cultivation with normal
fibroblasts to cancer-associated fibroblasts using reconfigu-
rable substrates. Dynamic changes in the biology of the
tumor cells can then be measured. It follows therefore that 5
one aspect of the invention relates to a method of exposing
tumor cells to non-tumor cells comprising the steps of:
culturing a plurality of cells of a first type on a first
component, wherein the cells of a first type are tumor cells;
culturing a plurality of cells of a second type on a second io
component; and
placing the first component at a distance from or in
contact with the second component for a time.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi- 15
tations, further comprising the step of determining changes
in biology of the cells of a first type.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are mammalian cells. 20
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are human cells.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi- 25
tations, wherein the cells of a first type are selected from the
group consisting of tumor cells of the anus, bladder, bile
duct, bone, brain, breast, cervix, colon/rectum, duodenum,
endometrium, esophagus, eye, gallbladder, head, neck, liver,
larynx, lung, mouth, pancreas, penis, prostate, kidney, ova- 30
ries, skin, stomach, testicles, and thyroid.
In certain embodiments, the present invention relates to
the aforementioned methods and any of the attendant limi-
tations, wherein the cells of a first type are tumor cells
selected from the group consisting of carcinoma, lympho- 35
mas, leukemias, sarcomas, mesotheliomas, gliomas, germi-
nomas, and choriocarcinomas.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are mammalian 40
cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are human cells.
In certain embodiments, the present invention relates to 45
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are selected from
the group consisting of cells of the anus, bladder, bile duct,
bone, brain, breast, cervix, colon/rectum, duodenum, endo-
metrium, esophagus, eye, gallbladder, head, neck, liver, 50
larynx, lung, mouth, pancreas, penis, prostate, kidney, ova-
ries, skin, stomach, testicles, and thyroid.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are cancer- 55
associated cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are fibroblasts.
In certain embodiments, the devices of the invention can 60
be used for drug discovery and toxicity testing. For example,
the reconfigurable substrates could be used to isolate specific
secreted soluble factors, for example a factor secreted by one
cell type and which has a protective or regenerative effect on
another cell type. The reconfigurable substrate would be 65
utilized to bring different cell types close together to allow
soluble interaction while preventing contact interaction.
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RNAi techniques would then used to knockdown expression
of specific soluble factors in order to isolate the critical
molecules. This method is suitable for models including but
not limited to liver hepatocytes co-cultivated with nonparen-
chymal support cells. Specifically, another aspect of the
invention relates to a method of isolating a soluble factor
comprising the steps of:
culturing a plurality of cells of a first type on a first
component;
culturing a plurality of cells of a second type on a second
component, wherein the cells of a second type secrete a
soluble factor; and
placing the first component at a distance from but not in
contact with the second component for a time.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, further comprising the step of using RNAi tech-
niques to knockdown expression of the soluble factor.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, further comprising the step of determining the effect
of the soluble factor on the cells of a first type.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the soluble factor has a protective or regen-
erative effect on the cells of a first type.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the soluble factor is selected from the group
consisting of BDNF, CNTF, Dvl-1, EGF, Endostatin, FGF,
GDNF, GM-CSF, Heregulin, IGF, IL, Insulin, Interferon,
7aggedl, M-CSF, NAG-1, NGF, NT, PDGF, PEDF, Prolac-
tin, SDF, SF-1, TGF, TNF, VEGF, and Wnt.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the soluble factor is selected from the group
consisting of fibrinogen, laminin, collagen IV, tenascin,
fibronectin, collagen, bovine pituitary extract, EGF, hepato-
cyte growth factor, keratinocyte growth factor, hydrocorti-
sone, dimethyl sulphoxide, recombinant human epidermal
growth factor, insulin, sodium selenite, transferrin, hydro-
cortisone, basic fibroblast growth factor, and leukemia
inhibitory factor.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are mammalian cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are human cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are selected from the
group consisting of cells of the anus, bladder, bile duct,
bone, brain, breast, cervix, colon/rectum, duodenum, endo-
metrium, esophagus, eye, gallbladder, head, neck, liver,
larynx, lung, mouth, pancreas, penis, prostate, kidney, ova-
ries, skin, stomach, testicles, and thyroid.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are mammalian
cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are human cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are selected from
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the group consisting of cells of the anus, bladder, bile duct,
bone, brain, breast, cervix, colon/rectum, duodenum, endo-
metrium, esophagus, eye, gallbladder, head, neck, liver,
larynx, lung, mouth, pancreas, penis, prostate, kidney, ova-
ries, skin, stomach, testicles, and thyroid.
The reconfigurable substrates if the invention could be
used in organ models (including but not limited to the liver)
for the screening of toxic compounds. Because cells in
mixed culture can be temporarily separated into individual
culture wells, compound exposure can be limited to a
specific subpopulation of cells in a mixed culture model,
reducing off-target effects. Also, culturing parenchymal and
nonparenchymal cells in the gap configuration may yield
more physiological models—cell contact is abrogated while
short-range soluble interactions are preserved, which can
better mimic certain in vivo physiologies.
The use of reconfigurable substrates could also be used to
separate cells in mixed culture into pure populations, to
facilitate clean measurements of cell behavior, whether at
the RNA, protein, or organelle activity level. This would be
useful, for example, in detecting toxic responses in which
the metabolite of one cell population is toxic to a second cell
population. Remarkably, use of reconfigurable substrates
simultaneously allows both intimate cell-cell interactions
(for example via short-range soluble signaling) and the
ability to separate into pure populations.
It follows that one aspect of the invention relates to a
method of selectively exposing a subpopulation of cells
from a mixed culture of cells to a compound comprising the
steps of:
culturing a mixed culture of cells comprising a plurality of
cells of a first type and a plurality of cells of a second type;
wherein the cells of a first type are cultured on a first
component, the cells of a second type are cultured on a
second component, and the first component is at a distance
from or in contact with the second component;
separating the first component from the second compo-
nent;
exposing the cells of a first type on the first component to
a compound for a time; and
placing the first component in proximity to or in contact
with the second component.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the compound is a toxic compound, expo-
sure to which results in the death of at least some of the cells
of a first type.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are mammalian cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are human cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are selected from the
group consisting of cells of the anus, bladder, bile duct,
bone, brain, breast, cervix, colon/rectum, duodenum, endo-
metrium, esophagus, eye, gallbladder, head, neck, liver,
larynx, lung, mouth, pancreas, penis, prostate, kidney, ova-
ries, skin, stomach, testicles, and thyroid.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are mammalian
cells.
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In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are human cells.
In certain embodiments, the present invention relates to
5 the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are selected from
the group consisting of cells of the anus, bladder, bile duct,
bone, brain, breast, cervix, colon/rectum, duodenum, endo-
metrium, esophagus, eye, gallbladder, head, neck, liver,
10 larynx, lung, mouth, pancreas, penis, prostate, kidney, ova-
ries, skin, stomach, testicles, and thyroid.
In another embodiment, reconfigurable substrates to cre-
ate liver models that support infection of a hepatitis virus. It
15 has been reported that co-cultivated liver endothelial cells
cause liver hepatocytes to be more susceptible to infection
by Hepatitis C. The reconfigurable substrates of the inven-
tion could be used to create a co-culture or tri -culture system
where endothelial cells maintain and influence hepatocytes
20 separated using the gap configuration. Such a system would
mimic in vivo physiology, in which sinusoidal endothelial
cells are near hepatocytes but separated by the space of
Disse. Also, since hepatocytes are maintained in a pure
monolayer on their individual comb fingers, evaluation by
25 microscopy or by RNA, protein, or organelle activity level
would be facilitated. In addition, configurable substrates
could be used to identify specific molecules that influence
hepatitis infectivity. For example, soluble factors from
endothelial cells that modulate hepatocyte susceptibility to
so hepatitis viruses could be identified using aforementioned
methods, such as siRNA knockdown.
In other words, another aspect of the invention relates to
a method of selectively exposing a mixed culture of cells to
a compound comprising the steps of:
35 culturing a mixed culture of cells comprising a plurality of
cells of a first type and a plurality of cells of a second type;
wherein the cells of a first type are cultured on a first
component, the cells of a second type are cultured on a
second component, and the first component is at a distance
40 from or in contact with the second component; and
exposing the cells of a first type on the first component
and the cells of a second type on a second component to a
compound for a time.
In certain embodiments, the present invention relates to
45 the aforementioned method and any of the attendant limi-
tations, wherein the compound is a toxic compound, expo-
sure to which results in the death of at least some of the cells
of a first type, some of the cells of a second type, or cells of
both types.
50 In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are mammalian cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
55 tations, wherein the cells of a first type are human cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are selected from the
group consisting of cells of the anus, bladder, bile duct,
6o bone, brain, breast, cervix, colon/rectum, duodenum, endo-
metrium, esophagus, eye, gallbladder, head, neck, liver,
larynx, lung, mouth, pancreas, penis, prostate, kidney, ova-
ries, skin, stomach, testicles, and thyroid.
In certain embodiments, the present invention relates to
65 the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are mammalian
cells.
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In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are human cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are selected from
the group consisting of cells of the anus, bladder, bile duct,
bone, brain, breast, cervix, colon/rectum, duodenum, endo-
metrium, esophagus, eye, gallbladder, head, neck, liver,
larynx, lung, mouth, pancreas, penis, prostate, kidney, ova-
ries, skin, stomach, testicles, and thyroid.
In another embodiment, in addition to the selective stimu-
lation described above, one can separate a subpopulation of
cells from a culture in order to assay those cells specifically;
this is known as selective interrogation. One example of
selective interrogation is shown in FIG. 11, where SEC cells
are separated out from a culture of many cell types, and a
Western Blot is performed on the purified SEC population.
Another example is in FIG. 15, where hepatocytes and 3T3
fibroblasts are separated before viability assays are per-
formed on each population.
It follows that one aspect of the invention relates to a
method of selectively assaying a subpopulation of cells from
a mixed culture of cells comprising the steps of:
culturing a mixed culture of cells comprising a plurality of
cells of a first type and a plurality of cells of a second type;
wherein the cells of a first type are cultured on a first
component, the cells of a second type are cultured on a
second component, and the first component is at a distance
from or in contact with the second component;
separating the first component from the second compo-
nent; and
assaying the cells of a first type, the cells of the second
type, or both.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the assay is a viability assay.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are mammalian cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are human cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a first type are selected from the
group consisting of cells of the anus, bladder, bile duct,
bone, brain, breast, cervix, colon/rectum, duodenum, endo-
metrium, esophagus, eye, gallbladder, head, neck, liver,
larynx, lung, mouth, pancreas, penis, prostate, kidney, ova-
ries, skin, stomach, testicles, and thyroid.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are mammalian
cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are human cells.
In certain embodiments, the present invention relates to
the aforementioned method and any of the attendant limi-
tations, wherein the cells of a second type are selected from
the group consisting of cells of the anus, bladder, bile duct,
bone, brain, breast, cervix, colon/rectum, duodenum, endo-
metrium, esophagus, eye, gallbladder, head, neck, liver,
larynx, lung, mouth, pancreas, penis, prostate, kidney, ova-
ries, skin, stomach, testicles, and thyroid.
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For all of the methods described herein, a variety of
different reconfigurable substrates can be used, for a variety
of times, in a variety of configurations. For example, In
certain embodiments, the present invention relates to any of
5 the aforementioned methods and any of the attendant limi-
tations, wherein the distance is in the range of about 1µm
to about 1,000µn.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
io limitations, wherein the distance is in the range of about 10
µm to about 200 µm.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the distance is in the range of about 50
15 µm to about 100 µm.
As used herein, fingers should be understood to be pro-
trusions like the teeth of a comb. See FIG. le for an example.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
20 limitations, wherein the first component comprises a first
plurality of fingers.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein each finger in the first plurality of
25 fingers is tapered.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the ratio of the lengths of the ends of
each finger in the first plurality of fingers is about 3:1.
30 In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the second component comprises sec-
ond a plurality of fingers.
In certain embodiments, the present invention relates to
35 any of the aforementioned methods and any of the attendant
limitations, wherein each finger in the second plurality of
fingers is tapered.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
40 limitations, wherein the ratio of the lengths of the ends of
each finger in the second plurality of fingers is about 3:1.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the length of each finger in the first
45 plurality of fingers is about 1 mm to about 50 mm.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the length of each finger in the first
plurality of fingers is about 1 mm to about 1 mm.
50 In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the length of each finger in the first
plurality of fingers is about 5 mm.
In certain embodiments, the present invention relates to
55 any of the aforementioned methods and any of the attendant
limitations, wherein the length of each finger in the second
plurality of fingers is about 1 mm to 50 mm.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
60 limitations, wherein the length of each finger in the second
plurality of fingers is about 1 mm to about 10 mm.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the length of each finger in the second
65 plurality of fingers is about 5 mm.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
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limitations, wherein the first plurality of fingers and the
second plurality of fingers are structured and arranged to
interdigitate with one another in a substantially coplanar
fashion.
As used herein latch is a type of mechanical hardware,
specifically a flexure, that is used to join two (or more)
objects or surfaces together while allowing for the regular or
eventual separation of the objects or surfaces. See, for
example, the snap-lock arm in FIG. le.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the first component comprises at least
or exactly two latches, and the latches are on opposite sides
of the first component.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the second component comprises at
least or exactly two latches, and the latches are on opposite
sides of the second component.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the first component comprises at least
or exactly two slots, and the slots are on opposite sides of the
first component.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the first component comprises at least
or exactly four slots, and the slots are on opposite sides of
the first component.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the first component comprises at least
or exactly six slots, and the slots are on opposite sides of the
first component.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the second component comprises at
least or exactly two slots, and the slots are on opposite sides
of the second component.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the second component comprises at
least or exactly four slots, and the slots are on opposite sides
of the second component.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the second component comprises at
least or exactly six slots, and the slots are on opposite sides
of the second component.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the slots are V-shaped.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the first component is fabricated from
silicon, polystyrene, quartz, glass, fused silica, SU-8,
PDMS, polypropylene, epoxies, polymers, ceramics or met-
als.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the second component is fabricated
from silicon, polystyrene, quartz, glass, fused silica, SU-8,
PDMS, polypropylene, epoxies, polymers, ceramics or met-
als.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
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limitations, wherein the first component is partially or com-
pletely coated with polystyrene.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
5 limitations, wherein the second component is partially or
completely coated with polystyrene.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the first component is partially or com-
10 pletely coated with collagen.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the second component is partially or
completely coated with collagen.
15 In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the first component is fabricated from
an optically transparent material.
In certain embodiments, the present invention relates to
20 any of the aforementioned methods and any of the attendant
limitations, wherein the first component is fabricated from
an optically translucent material.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
25 limitations, wherein the second component is fabricated
from an optically transparent material.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the second component is fabricated
30 from an optically translucent material.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the at least one cell of the first type is
different that the at least one cell of a second type.
35 In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, wherein the at least one cell of a first type is a
plurality of cells of a first type; the at least one cell of a
second type is a plurality of cells of a second type; and the
40 plurality of cells of the first type are different than the
plurality of cells of the second type.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, further comprising the step of altering the dis-
45 tance between the first component and the second compo-
nent.
In certain embodiments, the present invention relates to
any of the aforementioned methods and any of the attendant
limitations, further comprising the step of replacing the first
50 component or the second component with a third compo-
nent; wherein the third component wherein the third com-
ponent comprises at least one cell of a third type, different
from the first type of cell and the second type of cell.
55 EXEMPLIFICATION
The invention now being generally described, it will be
more readily understood by reference to the following
examples, which are included merely for purposes of illus-
60 tration of certain aspects and embodiments of the present
invention, and are not intended to limit the invention.
Materials. Collagen-I was purified from rat tails as pre-
viously described. Dunn, J. C., Tompkins, R. G. & Yarmush,
M. L. (1991) Biotechnol Prog 7, 237-45. Briefly, rat-tail
65 tendons were denatured in acetic acid, salt-precipitated,
dialyzed against HCl, and sterilized with chloroform. Since
the silicon substrates are opaque, a reflecting non-inverted
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microscope is required to inspect cells during culture. In
order to examine cultures without compromising sterility, a
microscopy system was required with an optical working
distance greater than the thickness of a covered culture plate.
A 5x objective with 36 mm working distance and a I0x
objective with a 38 mm working distance (Optical Product
Development, Lexington, Mass.) mounted on a Meiji
NIA655/05 head (Microscope World, Encinitas, Calif.) was
used.
Device Fabrication. Microfabrication facilities were uti-
lized at the University of California, Berkeley (U.C. Berke-
ley Microfabrication Laboratory, Berkeley, Calif.) and the
Massachusetts Institute of Technology (Microsystems Tech-
nology Laboratories, Cambridge, Mass.), using a similar
process at both locations. Device parts were fabricated using
commonly utilized MEMS fabrication methods. Good ref-
erences include papers by Ayon and coworkers (Ayon, A. A.,
Braff, R., Lin, C. C., Sawin, H. H. & Schmidt, M. A. (1999)
Journal of the Electrochemical Society 146, 339-349) and
Knobloch and coworkers (Knobloch, A. J., Wasilik, M.,
Fernandez-Pello, C. & Pisano, A. P. (2003) in 2003 ASME
International Mechanical Engineering Congress (American
Society of Mechanical Engineers, New York, N.Y. 10016-
5990, United States, Washington, D.C., United States), Vol.
5, pp. 115-123). Briefly, a double-sidepolished silicon wafer
(4", 500-µm, University Wafer, South Boston, Mass.) was
oxidized (1000° C., 02/H2O) to grow a 1-µm layer of silicon
dioxide. A layer of thick photoresist (Megaposit SPR220,
Rohm and Hass, Philadelphia, Pa.) was spin-coated, pat-
terned using a chrome mask and contact alignment (Karl
Suss MA6, SUSS MicroTec Inc., Waterbury Center, Vt.),
and developed (LDD-26W, Shipley, Marlborough, Mass.).
The patterned wafer, or device wafer, was then attached to
a handle wafer using a photoresist bond. After etching
through the oxide layer (He/CHF3/CF4 plasma), deep reac-
tive ion etching (ICP-ASE, Surface Technology Systems,
Newport, UK) was used to etch through the entire device
wafer as previously described (Knoblock, A. J., Wasilik, M.,
Fernandez-Pello, C. & Pisano, A. P. (2003) in 2003 ASME
International Mechanical Engineering Congress (American
Society of Mechanical Engineers, New York, N.Y. 10016-
5990, United States, Washington, D.C., United States), Vol.
5, pp. 115-123). The parts were then released in acetone and
cleaned in Piranha solution (4:1 H2SO4:H2O21 120° C., 10
min). Finally, the silicon surface was functionalized for cell
culture by spin-coating with polystyrene (100 mg/ml in
toluene, 2400 rpm, 1 min) followed by plasma treatment
(02, 200 mT, 200 W, 1 min), resulting in a surface compa-
rable to tissue culture plastic. Devices can be reused multiple
times (>20). Between experiments, the parts are cleaned in
toluene followed by Piranha solution, and polystyrene is
reapplied.
Alternative Approach to Device Fabrication. As described
above, the silicon device components can cut out of a silicon
wafer using a plasma etching process. In the first mask
design described above, each device component was cut
completely free of the silicon wafer at the end of the
plasma etch, the finished components had no connection
with the rest of the wafer. The components were still
attached by an adhesive to an underlying substrate. How-
ever, if the adhesive failed, which was not uncommon, the
components could detach during the etch process, resulting
in damage to the components. In an alternative mask design,
the components were not etched completely free but instead
remained connected to the rest of the wafer by small tethers.
After etching was complete, a dicing saw was used to cut the
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tethers and free the components. This method resulted in a
much higher yield (80% vs. 20%) in manufacturing.
The devices do not need to be made from silicon. For
example, polyurethane, polystyrene, epoxy, acrylic, glass, or
5 pre-strained polystyrene that shrinks upon heating, may be
used. Methods such as casting, molding, laser cutting,
water-jet cutting, machining, drill-press, injection molding,
knife cutting can aid in the preparation of the devices.
Cell Culture. Primary hepatocytes were isolated from 2-
io to 3-month-old adult female Lewis rats (Charles River
Laboratories, Wilmington, Mass.) weighing 180-200 g, fol-
lowing a modified procedure of Seglen (Seglen, P. O. (1976)
Methods Cell Biol 13, 29-83). Detailed procedures for
hepatocyte isolation and purification have been previously
15 described (Dunn, J. C., Tompkins, R. G. & Yarmush, M. L.
(1991) Biotechnol Prog 7, 237-45). Hepatocyte culture
medium consisted of Dulbecco's Modified Eagle Medium
with high glucose, 10% (v/v) fetal bovine serum, 0.5 U/mL
insulin, 7 ng/mL glucagon, 7.5 g/mL hydrocortisone, and
20 1% (v/v) penicillin-streptomycin. Swiss 3T3 fibroblasts
were purchased from ATCC (Manassas, Va.). J2-3T3 fibro-
blasts were the gift of Howard Green (Harvard Medical
School, Cambridge, Mass.; Rheinwald, J. G. & Green, H.
(1975) Cell 6, 331-43). Fibroblast culture medium consisted
25 of Dulbecco's Modified Eagle Medium with high glucose,
10% bovine calf serum, and 1% penicillinstreptomycin.
Device Actuation. Actuation was performed within a
biosafety cabinet using stainless steel tweezers (2-mm round
tips), sterilized in 70% ethanol before use. Substrates were
30 pushed or picked up using the round hole at the rear of each
part. It is possible for the parts to lock together misaligned
vertically. Therefore, after configuring substrates in the
intended state, plates were covered and examined under the
reflecting microscope to verify that interlocked fingers were
35 in-plane. Typically, roughly 5% of interlocked parts were
misaligned. To fix alignment, parts were simply separated
and locked back together.
Seeding Of Cells Onto Micromechanical Substrates.
Polystyrene-coated silicon substrates were placed into indi-
40 vidual wells on standard 12-well culture plates. Substrates
intended to support hepatocytes were incubated in collagen
solution (400 µg/ml in water) at 37° C. for at least 45 min.
To provide a flat, uniform surface for seeding, substrates
were each locked together with a complementary part, in the
45 contact mode. These complementary parts were utilized
only during cell seeding and were set aside afterwards.
Substrates were sterilized by soaking in 70% ethanol for 1
hand then washed twice in distilled water. Primary hepato-
cytes were typically seeded onto the male parts (no arms),
50 while fibroblasts (Swiss 3T3 or J2-3T3) were seeded onto
the female parts (with arms) (FIG. 1A). Cells were seeded at
500,000 cells/ml, with 1 mL per well, in the appropriate
culture medium and incubated for 60 min at 37° C. Plates
were shaken every 20 min to resuspend unattached cells.
55 After 60 min, unattached cells were aspirated, the substrate
was washed with culture medium, and seeding was repeated
with a fresh cell suspension. This process was repeated until
the substrate surface was fully coated, usually requiring 2-4
seeding cycles for hepatocytes and 2 seeding cycles for
60 fibroblasts. Within 6 hours of completing cell seeding, the
complementary parts were removed from each substrate.
Cell-coated substrates were then transferred to fresh wells
and incubated overnight in the appropriate medium. The
following day, a cell scraper (Fisher Scientific, Pittsburgh,
65 Pa.) was utilized to remove hepatocytes from the rear half of
the substrates, in order to leave only the cells attached
directly on the comb fingers (plus a border of roughly 1 mm
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due to imprecise manual scraping) (FIG. 1A, inset). Hepato-
cyte- and fibroblast-coated substrates were then assembled
into their initial configurations for a particular experiment.
Fluorescent Labels. Hepatocytes were labeled using cal-
cein AM (Molecular Probes, Eugene, Oreg.) at 5µg/ml in 5
hepatoctye medium. Swiss 3T3 fibroblasts were labeled
using CellTracker Orange CMTMR (Molecular Probes) at
0.5 µM in serum-free fibroblast medium. 72-3T3 fibroblasts
were labeled using CellTracker Blue CMAC (Molecular
Probes) at 2.5 µM in serum-free fibroblast medium. For io
high-magnification images, hepatocyte membranes were
labeled using PHK67 (Sigma-Aldrich, St. Louis, Mo.) at
1:1000 in Diluent C (Sigma). Fibroblast membranes were
labeled using Vybrant DiI (Molecular Probes) at 5µl/ml in
serum-free fibroblast medium. Cell nuclei were labeled 15
using Hoechst 33258 (Molecular Probes) at 0.001% in
hepatocyte medium.
Functional Assays. Albumin content was measured using
enzyme linked immunosorbent assays (MP Biomedicals,
Irvine, Calif.) with horseradish peroxidase detection and 20
3,31,5,51-tetramethylbenzidine (Pierce Biotechnology, Rock-
ford, Ill.) as a substrate (Dunn, J. C., Tompkins, R. G. &
Yarmush, M. L. (1991) Biotechnol Prog 7, 237-45). All
experiments were performed at least twice, with triplicate
samples for each condition. One representative outcome is 25
presented for each experiment, with similar trends observed
in multiple trials. Fluorescence quantification was per-
formed using MetaVue 6.2r0 software (Universal Imaging
Corporation, Downingtown, Pa.).
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INCORPORATION BY REFERENCE
All of the U.S. patents and U.S. published patent appli-
cations cited herein are hereby incorporated by reference.
35
EQUIVALENTS
Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention 40
described herein. Such equivalents are intended to be
encompassed by the following claims.
We claim:
1. A method for dynamically controlling a co-culture of
cells, comprising the steps of: 45
(a) culturing at least one cell of a first type on a first
micromechanical substrate, thereby providing a first
population of cells;
(b) culturing at least one cell of a second type on a second
micromechanical substrate, thereby providing a second 50
population of cells;
(c) placing the first micromechanical substrate in contact
with the second micromechanical substrate for a first
period of time, thereby providing direct cell-cell con-
tact between the first population of cells and the second 55
population of cells; and
(d) placing the first micromechanical substrate at a dis-
tance from the second micromechanical substrate for a
second period of time, thereby preventing direct cell-
cell contact between the first population of cells and the 60
second population of cells while providing exposure to
soluble factors produced by the first or second popu-
lation of cells, wherein the distance is in the range of
about 1µm to about 1,000 µm;
thereby dynamically controlling the co-culture of cells. 65
2. The method of claim 1, wherein the at least one cell of
a first type is a plurality of cells of a first type; the at least
30
one cell of a second type is a plurality of cells of a second
type; the cells of a first type are target cells comprising a
receptor; the cells of a second type secrete a soluble signal;
and the co-culturing results in exposing cells to cytokines.
3. The method of claim 2, further comprising the step of
determining the effect of a soluble signal exposure on the
cells of a first type.
4. The method of claim 2, wherein the cells of a first type
are mammalian cells.
5. The method of claim 2, wherein the cells of a first type
are human cells.
6. The method of claim 2, wherein the cells of a first type
comprise receptors for a member of the VEGF family,
VEGF-D, a member of the MIP family, MIP- ly, cerulo-
plasmin, nitric oxide, gases, or growth factors.
7. The method of claim 2, wherein the cells of a first type
comprise DLK, Dlk-1, a cadherin, or T- cadherin.
8. The method of claim 2, wherein the cells of a second
type are mammalian cells.
9. The method of claim 2, wherein the cells of a second
type are human cells.
10. The method of claim 2, wherein the cells of a second
type secrete hematopoietins, interferons, tumor necrosis
factors, chemokines, or a combination thereof.
11. The method of claim 2, wherein the cells of a second
type secrete a member of the VEGF family, VEGF-D, a
member of the MIP family, MIP-ly, ceruloplasmin, nitric
oxide, gases, or growth factors.
12. The method of claim 1, wherein the at least one cell
of a first type is a plurality of cells of a first type; the at least
one cell of a second type is a plurality of cells of a second
type; the cells of a first type are target cells comprising a
cytokine receptor; the cells of a second type secrete a
cytokine; and the co-culturing results in exposing cells to
cytokines.
13. The method of claim 12, further comprising the step
of determining the effect of a cytokine exposure on the cells
of a first type.
14. The method of claim 12, wherein the cells of a first
type are mammalian cells.
15. The method of claim 12, wherein the cells of a first
type are human cells.
16. The method of claim 12, wherein the cells of a first
type comprise cytokine receptors selected from the group
consisting of hematopoietin family receptors, interferon
family receptors, tumor necrosis factor family receptors, and
chemokine family receptors.
17. The method of claim 12, wherein the cells of a first
type comprise cytokine receptors selected from the group
consisting of receptors for IL-1 a, IL-I (3, IL-2, IL3, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-9, IL-12, IL-15, GM-CSF, IFN-a,
IFN-(3, IFN-y, TNF-a, TNF-(3, CD40, Fas, MIP-1 a, MIP-1
(3, RANTES, CCR5, and CXCR4.
18. The method of claim 12, wherein the cells of a second
type are mammalian cells.
19. The method of claim 12, wherein the cells of a second
type are human cells.
20. The method of claim 12, wherein the cells of a second
type secrete hematopoietins, interferons, tumor necrosis
factors, chemokines, or a combination thereof.
21. The method of claim 12, wherein the cells of a second
type secrete IL-1 a, IL-1 (3, IL2, IL-3, IL-4, IL-S, IL-6, IL-7,
IL-8, IL-9, IL-12, IL-15, GM-CSF, IFN- a, IFN-(3, IFN- y,
TNF-a, TNF- (3, CD40, Fas, MIP-1 a, MIP-1p, RANTES,
CCR5, or CXCR4.
22. The method of claim 1, wherein the distance is in the
range of about 10 µm to about 200 µm.
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23. The method of claim 1, wherein the distance is in the
range of about 50 µm to about 100 M.
24. The method of claim 1, wherein the first substrate is
fabricated from silicon, polystyrene, quartz, glass, fused
silica, SU-8, PDMS, polypropylene, epoxies, polymers, 5
ceramics or metals.
25. The method of claim 1, wherein the second substrate
is fabricated from silicon, polystyrene, quartz, glass, fused
silica, SU-8, PDMS, polypropylene, epoxies, polymers,
ceramics or metals. 10
26. The method of claim 1, wherein the first substrate is
partially or completely coated with polystyrene.
27. The method of claim 1, wherein the second substrate
is partially or completely coated with polystyrene.
28. The method of claim 1, wherein the first substrate is 15
partially or completely coated with collagen.
29. The method of claim 1, wherein the second substrate
is partially or completely coated with collagen.
30. The method of claim 1, wherein the first substrate is
fabricated from an optically transparent material. 20
31. The method of claim 1, wherein the first substrate is
fabricated from an optically translucent material.
32. The method of claim 1, wherein the second substrate
is fabricated from an optically transparent material.
33. The method of claim 1, wherein the second substrate 25
is fabricated from an optically translucent material.
34. The method of claim 1, wherein the at least one cell
of a first type is not the same as the at least one cell of the
second type.
* * * * * 30
